Clinical observation of Danlou tablets combined with aspirin for phlegm and blood stasis syndrome in coronary heart disease: impact on related serum factors.

OBJECTIVES

To investigate the effect of Danlou tablets combined with aspirin for treating phlegm and blood stasis syndrome in coronary heart disease (CHD).

METHODS

This study is a retrospective study, a total of 120 patients with phlegm and blood stasis syndrome with CHD were randomly assigned to either a control group (aspirin, 100 mg, once daily) or an observation group (Danlou tablets, 1.5 g, three times daily; aspirin, 100 mg, once daily) at a 1:1 ratio. Treatment was administered for 28 consecutive days. Pre- and post-treatment assessments included lipid profiles, hemorheology, inflammatory markers, serum phospholipase A2 (sPLA), lipoprotein-associated phospholipase 2 (LP-PLA), oxidized low-density lipoprotein (ox-LDL), monocyte chemotactic protein-1 (MCP-1), clinical efficacy, adverse events, and changes in TCM syndrome scores.

RESULTS

After 1 month of treatment, the observation group showed a significantly higher overall clinical efficacy rate (P = 0.038) compared to the control group. Post-treatment levels of sPLA, LP-PLA, ox-LDL, and MCP-1 decreased in both groups, with significantly lower levels in the observation group (P = 0.001, P = 0.013, P = 0.015). Additionally, reductions in small dense low-density lipoprotein cholesterol (sdLDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), fibrinogen, erythrocyte volume, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were significantly greater in the observation group than in the control group (P = 0.023, P = 0.023, P = 0.014, P = 0.012, P = 0.032, P = 0.019, P = 0.030).

CONCLUSIONS

The combination of Danlou tablets and aspirin significantly improves clinical symptoms in CHD patients with phlegm and blood stasis syndrome, reduces serum sPLA, LP-PLA, and ox-LDL levels, and inhibits inflammatory responses, suggesting this combination could provide a beneficial adjunctive therapy for managing CHD in these patients. This study serves as a reference for further research on Danlou tablets' role in CHD.